Artificial platelets suppressing deep vein thrombosis via competitive adhesion

Area of Science:

• Vascular Biology and Thrombosis
• Immunology and Inflammation
• Biomaterials and Nanotechnology

Background:

• Deep vein thrombosis (DVT) is a significant clinical challenge linked to pathological platelet adhesion at sites of vascular injury.
• The precise molecular mechanisms driving endothelial-dependent platelet adhesion in DVT remain incompletely understood.
• Endothelial adhesion molecule overexpression contributes to platelet aggregation in thrombotic events.

Purpose of the Study:

• To elucidate the molecular drivers of endothelial dysfunction and pathological platelet adhesion in DVT.
• To identify novel therapeutic targets and strategies for DVT treatment.
• To develop advanced biomaterials for targeted DVT intervention.

Main Methods:

• Integrated single-cell RNA sequencing (scRNA-seq) and functional validation to identify key molecular pathways.
• Utilized STING knockout mice to confirm the role of the stimulator of interferon genes (STING) pathway.
• Developed artificial platelets (Pm@Fng) using photopolymerization-membrane extrusion technology, incorporating forsythoside A (FA) and activated platelet membrane vesicles (APMVs).

Main Results:

• Aberrant STING activation was identified as a critical factor in endothelial dysfunction and pathological platelet adhesion.
• The STING-NLRP3 inflammasome pathway was confirmed to promote a prothrombotic microenvironment.
• Artificial platelets (Pm@Fng) demonstrated enhanced binding to von Willebrand factor (vWF), competitively inhibiting platelet adhesion and reducing thrombosis by 30% in a mouse DVT model.

Conclusions:

• Aberrant STING activation is a key therapeutic target for DVT.
• Forsythoside A (FA) acts as a potent STING inhibitor, and artificial platelets (Pm@Fng) offer a novel delivery system.
• This study presents a promising competitive adhesion-based therapeutic strategy for DVT and other endothelial injury-related diseases.